SCANDIUM ISOTOPE OF MASS 42

1957 ◽  
Vol 35 (10) ◽  
pp. 1190-1198 ◽  
Author(s):  
J. A. R. Cloutier ◽  
A. Henrikson
Keyword(s):  
Half Life ◽  
Ground States ◽  
Proton Bombardment ◽  
End Point ◽  
Positron Emission

A member of the odd–odd Z = N family, Sc42, has been produced by proton bombardment of a calcium target greatly enriched in Ca42. The positron emission, which alone is observed, has a measured half-life of 0.68 second, end point 4.8. Mev., and threshold 6.8 Mev. The superallowed transition is between ground states (J, T) tentatively described as Sc42 (0+, 1) and Ca42 (0+, 1).

DISCOVERY OF Pr137

1958 ◽  
Vol 36 (11) ◽  
pp. 1483-1486 ◽  
Author(s):  
Carl Dahlstrom ◽  
J. S. Foster ◽  
A. L. Thompson
Keyword(s):  
Gamma Rays ◽  
Half Life ◽  
Chemical Separation ◽  
Mass Determination ◽  
Proton Bombardment ◽  
End Point ◽  
Neutron Deficient Isotope ◽  
Positron Spectrum

The neutron-deficient isotope Pr137 has been discovered by proton bombardment of natural cerium, chemical separation, and mass determination. Its half-life is 1.5 ± 0.1 hours and the end point of its positron spectrum is 1.7 ± 0.1 Mev. No gamma rays were observed.

Production and radioassay of Tc-94m for PET studies

2003 ◽  
Vol 91 (10) ◽  
Author(s):  
Lawrence P. Szajek ◽  
M. Der ◽  
J. Divel ◽  
B. X. Huang ◽  
P. Plascjak ◽  
...  
Keyword(s):  
Half Life ◽  
Branching Ratio ◽  
Proton Bombardment ◽  
Point Energy ◽  
End Point ◽  
Quantitative Measurements ◽  
Short Half Life

SummaryThe radionuclide Tc-94m with its positron branching ratio of 72, positron end-point energy of 2.47MeV, and relatively short half-life of 52 minutes is suitable for quantitative measurements using PET. Tc-94m can be produced by proton bombardment of isotopically enriched [Mo-94]MoO

scholarly journals Search for Double Beta Decay of 106Cd with an Enriched 106CdWO4 Crystal Scintillator in Coincidence with CdWO4 Scintillation Counters

Universe ◽  
2020 ◽  
Vol 6 (10) ◽  
pp. 182
Author(s):  
Pierluigi Belli ◽  
R. Bernabei ◽  
V.B. Brudanin ◽  
F. Cappella ◽  
V. Caracciolo ◽  
...  
Keyword(s):  
Electron Capture ◽  
Beta Decay ◽  
Ground State ◽  
Half Life ◽  
Double Beta Decay ◽  
Cadmium Tungstate ◽  
Positron Emission ◽  
Double Electron ◽  
Theoretical Predictions ◽  
Crystal Scintillator

Studies on double beta decay processes in 106Cd were performed by using a cadmium tungstate scintillator enriched in 106Cd at 66% (106CdWO4) with two CdWO4 scintillation counters (with natural Cd composition). No effect was observed in the data that accumulated over 26,033 h. New improved half-life limits were set on the different channels and modes of the 106Cd double beta decay at level of limT1/2∼1020−1022 yr. The limit for the two neutrino electron capture with positron emission in 106Cd to the ground state of 106Pd, T1/22νECβ+≥2.1×1021 yr, was set by the analysis of the 106CdWO4 data in coincidence with the energy release 511 keV in both CdWO4 counters. The sensitivity approaches the theoretical predictions for the decay half-life that are in the range T1/2∼1021−1022 yr. The resonant neutrinoless double-electron capture to the 2718 keV excited state of 106Pd is restricted at the level of T1/20ν2K≥2.9×1021 yr.

The half-life of the first metastable state in 90Nb

1969 ◽  
Vol 47 (8) ◽  
pp. 949-951 ◽  
Author(s):  
J. S. Geiger ◽  
R. L. Graham ◽  
M. W. Johns
Keyword(s):  
Metastable State ◽  
Half Life ◽  
Published Data ◽  
Proton Bombardment ◽  
Tentative Assignment

A delayed γ activity, Eγ = 122.2 ± 0.2 keV, t1/2 = 18.82 ± 0.09 s, is observed following 10 MeV proton bombardment of targets of natural Zr and of natural Hf in which Zr is present as a contaminant. The present results taken together with other recently published data show that this activity arises from 90Zr(p,n)90Nbm. The tentative assignment of this 122 keV γ activity to 179Ta, which we proposed in an earlier publication, is withdrawn.

Half-life and high-energy positon end point of Sc40

1962 ◽  
Vol 33 ◽  
pp. 47-51 ◽  
Author(s):  
Felix Schweizer ◽  
J.Reginald Richardson
Keyword(s):  
Half Life ◽  
High Energy ◽  
End Point

End-point energy and half-life of the187Reβdecay

2000 ◽  
Vol 63 (1) ◽  
Author(s):  
M. Galeazzi ◽  
F. Fontanelli ◽  
F. Gatti ◽  
S. Vitale
Keyword(s):  
Half Life ◽  
Point Energy ◽  
End Point

scholarly journals The development of technology of Fludeoxyglucose (18F) for injection, laboratory analysis methods

2018 ◽  
pp. 51-58
Author(s):  
V. V. Kachaniuk ◽  
V. V. Trokhymchuk ◽  
S. Y. Sarychev
Keyword(s):  
Quality Control ◽  
Nuclear Medicine ◽  
Half Life ◽  
Pharmaceutical Research ◽  
18F Fluorodeoxyglucose ◽  
Positron Emission ◽  
Performance Specifications ◽  
Diagnosis Of Cancer ◽  
Object Of Study ◽  
First Time

18F-Fluorodeoxyglucose has optimal characteristics for use in nuclear medicine and is a priority among radiopharmaceuticals for the diagnosis of cancer by positron emission tomography (PET). 18F-Fluorodeoxyglucose has the longest half-life with the lowest energy of radiation, it allows to obtain PET images of high contrast at low dose loading on the patient. Low energy positron radiation provides high spatial resolution of PET images. However, the half-life of 18F-Fluorodeoxyglucose  is large enough to allow the transportation of radiopharmaceuticals from the centralized production site to diagnostic centers with PET scanners (the so-called PET satellite concept), and to extend the time limits of PET research and synthesis of radiopharmaceuticals [1]. The study is the development of technology and quality control methods to ensure quality at all stages of the production of radiopharmaceuticals 18F-Fluorodeoxyglucose, injection. There was justified 18F-Fluorodeoxyglucose production technology and quality control at all stages of production, based on complex research in the department producing radiopharmaceuticals Ukrainian Center of radiosurgery consisting Clinical Hospital «Feofaniya». Object of study – 18F-Fluorodeoxyglucose, injection, injection is used in nuclear medicine for PET diagnosis of cancer. We used the biopharmaceutical and pharmaceutical methods. For the first time based pharmaceutical research was the rational technology of diagnostic radiopharmaceuticals 18F-Fluorodeoxyglucose, injection for use in PET diagnosis of cancer patients. Methods of controlling drug 18F-Fluorodeoxyglucose, injection according monographs of the State Pharmacopoeia of Ukraine. On the basis of the analysis developed by established methods of control performance specifications and shelf life of radiopharmaceuticals 18F-Fluorodeoxyglucose, injection.

Advances in Immuno-PET in the Detection of Cancer and Assessment of Response to Therapy

2020 ◽  
Vol 27 ◽  
Author(s):  
Mian M. Alauddin ◽  
Leslie A. Khawli
Keyword(s):  
Half Life ◽  
Clinical Utility ◽  
Chelating Agents ◽  
Therapeutic Response ◽  
Rapid Development ◽  
Response To Therapy ◽  
Emission Tomography ◽  
Immune Checkpoints ◽  
Imaging Studies ◽  
Positron Emission

Background: Monoclonal antibodies (mAbs) against tumor-associated antigens have been shown to target tumors with specificity and selectivity; therefore, it was hypothesized that cancer could be treated with mAbs without side effects. In the early 1980s, clinical studies demonstrated that tumors could be visualized using radiolabeled mAbs. However, with the introduction of positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG), antibody-based imaging became less important because of its limited diagnostic accuracy. During the last two decades, a revival of imaging with radiolabeled mAbs has taken place, specifically PET with longer half-life isotopes. Development of immune checkpoints as targets for immunotherapy has opened opportunities for development of a wide variety of antibodies, such as anti-CTLA-4, anti-PD-L1, and anti-PD1. Thus, imaging with these antibodies radiolabeled with 89Zr or another long–half-life PET isotope, known as immuno-PET, has become mainstream. Objective: To review the rapid development of immuno-PET for the detection of cancer and assessment of therapeutic response combining surgery, radiation, chemotherapy, and/or immunotherapy. This review includes reports on the radiolabeling, imaging and clinical utility of 89Zr-, 64Cu-, and 124I-labeled mAbs. Results: More than 120 research and review articles on immuno-PET were reviewed. Conclusion: Many mAbs have been developed and used for treatment of cancer; however, a limited number of antibodies have been radiolabeled for immuno-PET. While much progress has been made with the therapeutic applications of mAbs, immuno-PET for diagnosis and treatment assessment needs more work. Improved chelating agents and extensive imaging studies are needed to refine immuno-PET for the diagnosis of cancers and assessment of response to therapy.

scholarly journals DELAYED PROTONS FOLLOWING THE DECAY OF ARGON-33

1965 ◽  
Vol 43 (3) ◽  
pp. 418-421 ◽  
Author(s):  
J. C. Hardy ◽  
R. I. Verrall
Keyword(s):  
Lithium Chloride ◽  
Half Life ◽  
Proton Spectrum ◽  
Proton Bombardment

The delayed-proton precursor 33Ar has been produced by proton bombardment of a lithium chloride target in the internal beam of the McGill synchrocyclotron. The half-life of 33Ar was measured to be (178 ± 10) msec. To explain the delayed proton spectrum, two new levels, at 5.55 and 7.55 MeV, in 33Cl are proposed. It is also proposed that the former is the expected first T = 3/2 state in that nucleus.

scholarly journals Precise measurements of theBk97249ground state half-life and theβ−-decay end-point energy

2014 ◽  
Vol 90 (4) ◽  
Author(s):  
J. Chen ◽  
I. Ahmad ◽  
J. P. Greene ◽  
F. G. Kondev
Keyword(s):  
Half Life ◽  
Point Energy ◽  
End Point
Sign in / Sign up

Export Citation Format

Share Document